Stories

a test story to check media.  website uses cookies to improve user experience. You may review Cookies Settings by following the link, or Reject All or Accept All Cookies from this page by using the buttons. You are directing us…

a test story to check media.  website uses cookies to improve user experience. You may review Cookies Settings by following the link, or Reject All or Accept All Cookies from this page by using the buttons. You are directing us…

In 2023, we entered the next phase of our journey of growth and innovation, reinforcing our position as a leading mid-sized biopharmaceutical company. With a sharp focus on our three therapy areas of Oncology, Rare Diseases, and Neuroscience, we achieved total sales of €3,128 m.

test

The acquisition of Albireo and the integration of over 25 new programs into our pipeline since 2020 will enable us to continue to deliver groundbreaking therapies to patients worldwide in the coming years.